Serum Mannose-Binding Lectin Levels in Asthma and Allergic Bronchopulmonary Aspergillosis.

IF 2.9 3区生物学 Q2 MYCOLOGY

Mycopathologia Pub Date : 2025-07-30 DOI:10.1007/s11046-025-00975-1

Inderpaul Singh Sehgal, Hansraj Choudhary, Valliappan Muthu, Sahajal Dhooria, Kuruswamy Thurai Prasad, Shivaprakash M Rudramurthy, Ashutosh Nath Aggarwal, Mandeep Garg, Arunaloke Chakrabarti, Ritesh Agarwal

{"title":"Serum Mannose-Binding Lectin Levels in Asthma and Allergic Bronchopulmonary Aspergillosis.","authors":"Inderpaul Singh Sehgal, Hansraj Choudhary, Valliappan Muthu, Sahajal Dhooria, Kuruswamy Thurai Prasad, Shivaprakash M Rudramurthy, Ashutosh Nath Aggarwal, Mandeep Garg, Arunaloke Chakrabarti, Ritesh Agarwal","doi":"10.1007/s11046-025-00975-1","DOIUrl":null,"url":null,"abstract":"<p><p>Mannose-binding lectin (MBL) contributes to innate immunity against Aspergillus fumigatus. We assessed the role of reduced MBL levels in asthma patients with and without allergic bronchopulmonary aspergillosis (ABPA). In this prospective cross-sectional study, we enrolled 154 adults: 48 with asthma, 27 with Aspergillus-sensitized asthma (ASA, A. fumigatus-IgE ≥ 0.35 kUA/L), and 79 with ABPA. Serum MBL levels were quantified using enzyme-linked immunosorbent assay. Reduced MBL levels were defined using three thresholds (< 200, < 359, and < 500 ng/mL). The prevalence of reduced MBL levels did not differ significantly among the groups at any threshold. However, mean MBL levels were significantly lower in patients with ABPA (961 ng/mL) compared to asthma (1159 ng/mL) and ASA (1593 ng/mL; p = 0.048). Among ABPA patients, reduced MBL levels (≤ 359 ng/mL) were not associated with significant differences in clinical features, immunological markers, lung function, or radiology.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":"190 5","pages":"68"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-025-00975-1","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mannose-binding lectin (MBL) contributes to innate immunity against Aspergillus fumigatus. We assessed the role of reduced MBL levels in asthma patients with and without allergic bronchopulmonary aspergillosis (ABPA). In this prospective cross-sectional study, we enrolled 154 adults: 48 with asthma, 27 with Aspergillus-sensitized asthma (ASA, A. fumigatus-IgE ≥ 0.35 kUA/L), and 79 with ABPA. Serum MBL levels were quantified using enzyme-linked immunosorbent assay. Reduced MBL levels were defined using three thresholds (< 200, < 359, and < 500 ng/mL). The prevalence of reduced MBL levels did not differ significantly among the groups at any threshold. However, mean MBL levels were significantly lower in patients with ABPA (961 ng/mL) compared to asthma (1159 ng/mL) and ASA (1593 ng/mL; p = 0.048). Among ABPA patients, reduced MBL levels (≤ 359 ng/mL) were not associated with significant differences in clinical features, immunological markers, lung function, or radiology.

查看原文本刊更多论文

哮喘和过敏性支气管肺曲霉菌病血清甘露糖结合凝集素水平。

甘露糖结合凝集素（MBL）有助于对烟曲霉的先天免疫。我们评估了MBL水平降低在伴有和不伴有过敏性支气管肺曲霉病（ABPA）的哮喘患者中的作用。在这项前瞻性横断面研究中，我们招募了154名成年人：48名哮喘患者，27名曲霉致敏哮喘患者（ASA， A. fumigatus-IgE≥0.35 kUA/L）， 79名ABPA患者。采用酶联免疫吸附法定量测定血清MBL水平。MBL水平的降低使用三个阈值(

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mycopathologia 生物-真菌学

CiteScore

6.80

自引率

3.60%

发文量

审稿时长

3 months

期刊介绍： Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.